FY2025 Earnings Estimate for ABT Issued By Leerink Partnrs

Key Points

• Leerink Partners has raised its earnings estimates for Abbott Laboratories, projecting FY2025 earnings per share at $5.15, slightly above the previous forecast of $5.13.
• Abbott Laboratories reported a quarterly earnings per share of $1.30, meeting consensus estimates, with revenues of $11.37 billion for the quarter, reflecting a year-over-year increase of 6.9%.
• The company announced a quarterly dividend of $0.59 per share, which equates to an annual yield of 1.8%, with payments scheduled for November 17th.

Abbott Laboratories (NYSE:ABT - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Abbott Laboratories in a report released on Wednesday, October 15th. Leerink Partnrs analyst M. Kratky now expects that the healthcare product maker will post earnings per share of $5.15 for the year, up from their previous forecast of $5.13. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.14 per share. Leerink Partnrs also issued estimates for Abbott Laboratories' Q3 2026 earnings at $1.45 EPS, Q4 2026 earnings at $1.66 EPS, FY2026 earnings at $5.67 EPS and FY2027 earnings at $6.24 EPS.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company had revenue of $11.37 billion during the quarter, compared to analysts' expectations of $11.40 billion. During the same period last year, the company posted $1.21 earnings per share. The business's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS.

ABT has been the subject of several other reports. Barclays raised their price target on shares of Abbott Laboratories from $159.00 to $162.00 and gave the stock an "overweight" rating in a report on Friday. Wells Fargo & Company raised their price target on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an "overweight" rating in a report on Thursday. Weiss Ratings restated a "buy (b)" rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Evercore ISI decreased their price target on shares of Abbott Laboratories from $144.00 to $142.00 and set an "outperform" rating for the company in a report on Wednesday, October 15th. Finally, William Blair upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $147.61.

Abbott Laboratories Stock Performance

Shares of ABT opened at $128.69 on Monday. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company has a 50-day moving average of $132.38 and a two-hundred day moving average of $131.54. The stock has a market cap of $223.98 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 2.44 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.46% of the company's stock.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors have recently modified their holdings of the company. IMG Wealth Management Inc. raised its position in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock valued at $26,000 after purchasing an additional 167 shares during the period. Hughes Financial Services LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $27,000. Abound Financial LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $28,000. Elequin Capital LP bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $30,000. Finally, Anfield Capital Management LLC raised its position in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock valued at $32,000 after purchasing an additional 104 shares during the period. Institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.